PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.
PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.
PharmGKB contains no Clinical Variants that meet the highest level of criteria.
Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.
The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.
|Alternate Names:||MLL; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila)|
|Alternate Symbols: ||ALL-1; CXXC7; HRX; HTRX1; KMT2A; MLL1A; TRX1|
|PharmGKB Accession Id:||PA241|
|Cytogenetic Location:||chr11 : q23.3 - q23.3|
|GP mRNA Boundary†:||chr11 : 118307205 - 118397539|
|GP Gene Boundary†:||chr11 : 118297205 - 118400539|
UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.View on UCSC Browser
Publications related to KMT2A: 6
The following icons indicate that data of a certain type is available:
- DG Dosing Guideline information is available
- DL Drug Label information is available
- CA High-level Clinical Annotation is available
- VA Variant Annotation is available
- VIP VIP information is available
- PW Pathway is available
[ close ]
||Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. Pharmacogenomics. 2013. Jensen Brian C, et al.|
||Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. The New England journal of medicine. 2008. Schlenk Richard F, et al.|
||Polymorphisms in the MLL breakpoint cluster region (BCR). Human genetics. 2003. Echlin-Bell Deborah R, et al.|
||Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood. 2003. Relling Mary V, et al.|
||Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1998. Relling M V, et al.|
||Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood. 1997. Chen C L, et al.|